Immuno Technologies

What Immuno Technologies does

Immuno Technologies, Inc. (ITi) is a Memphis, Tennessee-based preclinical biotechnology company founded in 2012 and funded since 2014 exclusively through non-dilutive NIH/NIAID SBIR grants. The company develops preventatives (vaccines and monoclonal antibody candidates) and immunodiagnostic assays for spirochetal diseases, with Lyme disease as the primary focus and leptospirosis as a secondary vertical. Its lead asset, LymeMist™, is an intranasal prime-boost vaccine that delivers a modified full-length OspA protein (with the putative autoantigenic epitope replaced) via a parainfluenza 5 (PIV5) viral vector; preliminary murine data showed 100% protective efficacy against tick-transmitted B. burgdorferi challenge four months after the first dose, and the program is currently in SBIR Phase II IND-enabling studies through June 2025.

The underlying technology platform pairs the PIV5 vector (licensed in partnership with Cyanvac, which has a PIV5-based candidate in human trials) with a proprietary OspA antigen design, applied across vaccine and lab-on-chip diagnostic programs. The company operates no commercial sales function; its stated go-to-market is to secure intellectual property through proof-of-concept and pre-IND work, then license or form strategic alliances with parties capable of commercialization. To date, Immuno Technologies has executed five SBIR-funded projects with multiple academic partners, including the University of Tennessee, Tulane University, Iowa State University, UT Health Science Center, and the Arkansas Biosciences Institute, and has no disclosed venture capital, private equity, or acquisition activity.

Name

Immuno Technologies

Legal name

Immuno Technologies, Inc.

Website

https://immunotechnologies.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Preclinical Vaccine and Diagnostic Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF), Adult Vaccines (HLAIAEAB)

Keywords

• Preclinical vaccine research
• Infectious disease biologics
• Lyme disease vaccines
• Diagnostic assay development
• Viral vector vaccines

Headquarters

HQ city

Memphis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. SBIR Grant Funding: Non-dilutive SBIR (Small Business Innovation Research) funding from NIH since 2014. The company operates as a preclinical research organization funded primarily through government grants rather than product revenue.

Distribution channels1 record

Marketing channels2 records

Core offering

Immuno Technologies conducts preclinical research and development of biologics targeting spirochetal infectious diseases, principally a needle-free intranasal Lyme disease vaccine (LymeMist™) delivered via a proprietary parainfluenza 5 (PIV5) viral vector expressing a modified OspA antigen, and point-of-care serodiagnostic assays for Lyme disease and leptospirosis. The company has no commercialized products and intends to monetize through licensing agreements or the creation of new companies once IND-enabling milestones are achieved.

Product overview

Immuno Technologies is a preclinical research company focused on developing biologics for spirochetal diseases. The company operates two product lines: (1) Vaccines including the LymeMist™ intranasal vaccine against Lyme disease (active development), and completed projects for Lyme disease vaccine production in maize; and (2) Diagnostic assays including point-of-care assays for leptospirosis and Lyme disease serodiagnosis, and an antibody isotyping assay for Lyme disease staging. The company is SBIR-funded and conducts preclinical development through proof-of-concept and pre-IND enabling studies, seeking strategic alliances for commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• LymeMist™: Trademarked intranasal vaccine candidate against Lyme disease, using parainfluenza 5 (PIV5) viral-vector delivery technology. The vaccine is designed for prime-boost administration via a needle-free intranasal delivery method.

Products and services

• LymeMist™ Intranasal Lyme Disease Vaccine An intranasal parainfluenza 5 (PIV5) viral-vector delivered vaccine candidate against human Lyme disease using a modified full-length OspA antigen (OspABPBPk) with the putative autoantigenic epitope replaced. Administered in a two-dose needle-free prime-boost schedule. Currently in preclinical SBIR Phase II development (5R44AI167605-03) intended for the U.S. market.
• Lab-on-a-Chip Point-of-Care Assay for Lyme Disease Serodiagnosis A lab-on-a-chip point-of-care diagnostic assay for rapid serodiagnosis of Lyme disease. Developed under SBIR Phase II grant R44AI096551 (07/01/2014 to 04/30/2017).
• Point-of-Care Assay for Leptospirosis Serodiagnosis A point-of-care assay for the serodiagnosis of leptospirosis. Developed under SBIR Phase I grant R43AI136551 (12/15/2017 to 07/31/2020).
• Antibody Isotyping Assay for Lyme Disease Stage Discrimination An antibody isotyping assay to discriminate disease stages and enable early diagnosis of Lyme disease. Developed under SBIR Phase I grant R43AI155211 (07/02/2020 to 03/31/2023).
• Low-Cost Maize-Production Lyme Disease Vaccine Low-cost production platform for a Lyme disease vaccine expressed in maize. Developed under SBIR Phase I grant R43AI152650 (03/02/2021 to 02/29/2024).

Quantifiable outcome

• 100% protective efficacy against B. burgdorferi infection in mice challenged 4 months after first dose
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core.

• UT Health Science CentercoreStrategic or Co-development PartnerAcademic research partnership for preclinical vaccine and diagnostic assay development. Collaborating on Lyme disease and leptospirosis research projects.
• The University of Tennessee KnoxvillecoreStrategic or Co-development PartnerUniversity research collaboration supporting vaccine development and biologics research. Partner in SBIR-funded research programs.
• Iowa State UniversitycoreStrategic or Co-development PartnerAcademic research partnership contributing to preclinical research capabilities for vaccine and assay development.
• CyanvaccoreStrategic or Co-development PartnerPartner providing PIV5 viral vector platform technology for vaccine development. PIV5 is used as a safe delivery vector, with one vaccine using this platform undergoing human clinical trial.
• UT Institute of AgriculturecoreStrategic or Co-development PartnerResearch partnership supporting agricultural and biomedical research collaborations related to zoonotic diseases.
• Tulane UniversitycoreStrategic or Co-development PartnerAcademic partnership contributing research expertise to preclinical vaccine development and diagnostic assay programs.
• ABI (Arkansas Biosciences Institute)coreStrategic or Co-development PartnerResearch institute partnership supporting bioscience research initiatives related to vaccine and diagnostic development.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Valneva: Valneva, partnered with Pfizer, is developing VLA15, a recombinant OspA-based Lyme disease vaccine currently in Phase 3 clinical trials. It is the most directly comparable Lyme vaccine competitor and the leading benchmark for LymeMist™'s commercial viability.
• Cyanvac: Cyanvac is Immuno Technologies' PIV5 viral-vector platform partner and is itself developing PIV5-based vaccines, including a candidate that has advanced into human clinical trials. It is both a collaborator and the closest peer in PIV5 vaccine technology.

Broad incumbents

• Pfizer: Pfizer commercialized the original LYMErix Lyme vaccine (later withdrawn) and is currently partnered with Valneva on VLA15. As a major vaccine manufacturer, it sets the bar for what a successful human Lyme vaccine would need to look like commercially.
• Moderna: Moderna operates an mRNA vaccine platform with broad applicability and has signaled interest in expanding beyond COVID-19 into additional infectious-disease targets. It represents a potential platform competitor that could pivot mRNA technology into Lyme disease.
• Sanofi Pasteur: Sanofi Pasteur is one of the largest global vaccine manufacturers with deep expertise in both pediatric and adult vaccines. It is the type of large incumbent that could partner with or acquire a preclinical Lyme vaccine asset like LymeMist™.
• GSK (GlaxoSmithKline): GSK operates a major vaccines business and has historically been active in tick-borne disease R&D. It is a logical strategic acquirer or licensing partner for a novel Lyme vaccine candidate.
• Merck & Co. Merck has a substantial vaccines franchise and the financial capacity to acquire or partner on a Lyme vaccine program. Its broad infectious-disease portfolio makes it a credible potential strategic partner for Immuno Technologies.
• BioNTech: BioNTech's mRNA vaccine platform is theoretically applicable to Lyme disease antigens such as OspA. As a well-capitalized infectious-disease platform player, it represents a potential competitor or acquirer of Lyme vaccine technology.

Emerging players

• Novavax: Novavax is a protein-subunit vaccine developer that, like Immuno Technologies, relies on a defined antigen platform and has historically operated from a small-cap, R&D-focused base. It is comparable as a similarly positioned vaccine platform company.
• Dynavax Technologies: Dynavax is a small-cap vaccine and adjuvant company that partners with larger manufacturers to commercialize its products. Its licensing-driven business model closely mirrors the strategic-alliance commercialization path Immuno Technologies describes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immuno Technologies